[Federal Register: March 30, 2009 (Volume 74, Number 59)]
[Notices]
[Page 14138-14139]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr30mr09-64]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of Federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Method of Making a Vaccine
Description of Technology: Current invention describes the methods
to prepare vaccines, and to use such vaccines in the vaccination and
treatment of human disease, e.g., the human immunodeficiency virus
(HIV) infections and cancer. More specifically, the present invention
provides a vaccine and method for making same which is effective to
elicit a desired antibody against a target antigen comprising a primary
immunogen and a secondary immunogen, wherein the primary immunogen is
effective to elicit B cell receptors (BCRs) that are on the
maturational pathway of the desired antibody and have an intermediate
degree of somatic mutational diversity, and the secondary immunogen
comprises an epitope of the desired target antibody and is effective to
further diversify the BCRs sufficient to form mature BCRs having the
identical or substantially identical sequence as the desired antibody.
Applications: Treatment and prevention of HIV infection.
Advantages: Novel methods to design vaccines for HIV treatment and
prevention; May also be used for designing vaccines for cancer
treatment.
Development Status: In vitro data available.
Market: HIV therapeutics and preventatives.
Inventor: Dimiter S. Dimitrov (NCI).
Publications:
1. MY Zhang, Y Shu, S Phogat, X Xiao, F Cham, P Bouma, A Choudhary,
YR Feng, I Sanz, S Rybak, CC Broder, GV Quinnan, T Evans, DS Dimitrov.
Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab
selected by sequential antigen panning of a phage display library. J
Immunol Methods. 2003 Dec;283(1-2):17-25.
2. MY Zhang, X Xiao, IA Sidorov, V Choudhry, F Cham, PF Zhang, P
Bouma, M Zwick, A Choudhary, DC Montefiori, CC Broder, DR Burton, GV
Quinnan Jr, DS Dimitrov. Identification and characterization of a new
cross-reactive human immunodeficiency virus type 1-neutralizing human
monoclonal antibody. J Virol. 2004 Sep;78(17):9233-9242.
3. Z Zhu, AS Dimitrov, KN Bossart, G Crameri, KA Bishop, V
Choudhry, BA Mungall, YR Feng, A Choudhary, MY Zhang, Y Feng, LF Wang,
X Xiao, BT Eaton, CC Broder, DS Dimitrov. Potent neutralization of
Hendra and Nipah viruses by human monoclonal antibodies. J Virol. 2006
Jan;80(2):891-899.
4. MY Zhang, V Choudhry, IA Sidorov, V Tenev, BK Vu, A Choudhary, H
Lu, GM Stiegler, HW Katinger, S Jiang, CC Broder, DS Dimitrov.
Selection of a novel gp41-specific HIV-l neutralizing human antibody by
competitive antigen panning. J Immunol Methods. 2006 Dec 20;317(1-
2):21-30.
5. V Choudhry, MY Zhang, IA Sidorov, JM Louis, I Harris, AS
Dimitrov, P Bouma, F Cham, A Choudhary, SM Rybak, T Fouts, DA
Montefiori, CC Broder, GV Quinnan Jr, DS Dimitrov. Cross-reactive HIV-1
neutralizing monoclonal antibodies selected by screening of an immune
human phage library against an envelope glycoprotein (gpI40) isolated
[[Page 14139]]
from a patient (R2) with broadly HIV-l neutralizing antibodies.
Virology. 2007 Jun 20;363(1):79-90.
6. Z Zhu, S Chakraborti, Y He, A Roberts, T Sheahan, X Xiao, LE
Hensley, P Prabakaran, B Rockx, IA Sidorov, D Corti, L Vogel, Y Feng,
JO Kim, LF Wang, R Baric, A Lanzavecchia, KM Curtis, GJ Nabel, K
Subbarao, S Jiang, DS Dimitrov. Potent cross-reactive neutralization of
SARS coronavirus isolates by human monoclonal antibodies. Proc Natl
Acad Sci USA. 2007 Jul 17;104(29):12123-12128.
7. Z Zhu, KN Bossart, KA Bishop, G Crameri, AS Dimitrov, JA
McEachern, Y Feng, D Middleton, LF Wang, CC Broder, DS Dimitrov.
Exceptionally potent cross-reactive neutralization of Nipah and Hendra
viruses by a human monoclonal antibody. J Infect Dis. 2008 Mar
15;197(6):846-853.
8. MY Zhang, BK Vu, A Choudhary, H Lu, M Humbert, H Ong, M Alam, RM
Ruprecht, G Quinnan, S Jiang, DC Montefiori, JR Mascola, CC Broder, BF
Haynes, DS Dimitrov. Cross-reactive human immunodeficiency virus type
1-neutralizing human monoclonal antibody which recognizes a novel
conformational epitope on gp41 and lacks reactivity against self
antigens. J Virol. 2008 Jul;82(14):6869-6879.
Patent Status: U.S. Provisional Application No. 61/104,706 filed 11
Oct 2008 (HHS Reference No. E-322-2008/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Sally Hu, Ph.D.; 301-435-5606; HuS@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate, or
commercialize this method. Please contact John D. Hewes, Ph.D. at 301-
435-3121 or hewesj@mail.nih.gov for more information.
Anti-Hepatitis C Virus Activity of the Protein Scytovirin (SVN)
Description of Technology: The invention provides compositions and
methods of use for potent anti-HCV protein scytovirin to prevent and
treat HCV infections. Currently there is neither effective treatment
nor vaccine against HCV infection and chronic HCV infection may lead to
liver cancer and death. Scytovirin can be used alone or in combination
with other anti-HCV drugs for HCV treatment and prevention.
Applications: The treatment and prevention of HCV infections.
Advantages: Potent anti-HCV activity; Can be applied both
systematically or locally.
Development Status: In vitro data available.
Market: HCV therapeutics and preventatives.
Inventors: Barry R. O'Keefe et al. (NCI).
Publications: Data collection and manuscripts may be submitted in
2009.
Patent Status: U.S. Provisional Application No. 61/137,511 filed 31
Jul 2008 (HHS Reference No. E-161-2008/0-US-01).
Related Technology: HHS Reference No. E-017-2002/0--Scytovirins and
Related Conjugates, Antibodies, Compositions, Nucleic Acids, Vectors,
Host Cells, Methods of Production and Methods of Using Scytovirin.
Licensing Status: Available for licensing.
Licensing Contact: Sally Hu, Ph.D.; 301-435-5606, HuS@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
CCR Molecular Targets Development Program is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize this
technology. Please contact John D. Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
Dated: March 19, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E9-6933 Filed 3-27-09; 8:45 am]
BILLING CODE 4140-01-P